ARYA Sciences Acquisition Corp II (ARYBU) Stock Price, News & Analysis

Company Overview

ARYA Sciences Acquisition Corp II was a blank-check company, also known as a special purpose acquisition company (SPAC), formed to identify and acquire a business in the biotechnology, pharmaceutical, medical technology, or other life sciences sectors. The company did not have significant operating activities or commercial products of its own before completing a business combination.

In 2021, ARYA Sciences Acquisition Corp II completed a merger with Cerevel Therapeutics, a biopharmaceutical company focused on developing treatments for diseases of the nervous system, including schizophrenia, Parkinson’s disease, and related neurological and psychiatric conditions. Following the transaction, the combined company operated as Cerevel Therapeutics Holdings, Inc., and ARYA Sciences Acquisition Corp II ceased operating as an independent acquisition vehicle.

ARYA Sciences Acquisition Corp II was sponsored by affiliates of Perceptive Advisors, an investment firm focused on the life sciences industry. Its securities included publicly traded units under the symbol ARYBU. Because the company was established primarily to pursue a transaction rather than to provide products or services directly, information about its standalone operations and geographic presence is limited.

Key Stats

• Today's Range: $10.39 to $10.90
• 50-Day Range: $10.39 to $10.39
• 52-Week Range: $10.00 to $13.46
• Volume: 700 shs
• Average Volume: 60,438 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ARYBU
• CIK: N/A
• Web: cerevel.com
• Phone: 212 284 2300
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A